CBD shows clinical promise for epilepsy and early signals for anxiety, psychosis, and addiction
CBD has established clinical evidence for seizure disorders and childhood epilepsies, with promising but less mature evidence for anxiety, psychosis, Parkinson's quality of life, and addictive behaviors.
Quick Facts
What This Study Found
CBD is safe, well-tolerated, and efficacious for several seizure disorders. It shows anxiolytic effects in social anxiety disorder and antipsychotic effects in schizophrenia. Parkinson's patients reported improved sleep and quality of life. No human studies existed for Alzheimer's or unipolar depression at the time of review.
Key Numbers
CBD demonstrated anti-epileptic, anti-oxidant, anti-inflammatory, antipsychotic, anxiolytic, and antidepressant properties in preclinical studies. Clinical efficacy confirmed for seizure disorders. CBD treatment alone was insufficient for Huntington's disease choreic movements.
How They Did This
Narrative review summarizing selected preclinical and clinical studies examining CBD effects across neuropsychiatric disorders including epilepsy, psychosis, anxiety, Parkinson's, Huntington's, addiction, Alzheimer's, and depression.
Why This Research Matters
This review maps the landscape of CBD research across neuropsychiatric conditions, clearly distinguishing where clinical evidence exists (epilepsy) from where only preclinical data supports therapeutic potential (depression, Alzheimer's).
The Bigger Picture
The gap between preclinical promise and clinical evidence for CBD is large for most neuropsychiatric conditions. While epilepsy has strong trial data, conditions like depression and Alzheimer's have zero human studies, making consumer claims about CBD for these conditions premature.
What This Study Doesn't Tell Us
Narrative review with inherent selection bias in study inclusion. Many conditions discussed have only preclinical evidence. Sample sizes in existing clinical trials are generally small. Long-term safety data are limited.
Questions This Raises
- ?Will human trials confirm CBD's preclinical antidepressant effects?
- ?What is the optimal dosing for each neuropsychiatric condition?
- ?Can CBD be combined with existing treatments for synergistic benefit?
Trust & Context
- Key Stat:
- CBD clinically effective for epilepsy; no human studies yet for depression or Alzheimer's
- Evidence Grade:
- Moderate: narrative review covering substantial preclinical and clinical literature, but non-systematic methodology.
- Study Age:
- Published in 2019.
- Original Title:
- Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
- Published In:
- Progress in molecular biology and translational science, 167, 25-75 (2019)
- Authors:
- Elsaid, Sonja(2), Kloiber, Stefan(6), Le Foll, Bernard(40)
- Database ID:
- RTHC-02024
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What conditions does CBD actually have clinical evidence for?
As of this review, CBD has the strongest clinical evidence for seizure disorders and childhood epilepsies. There are smaller trials supporting effects on social anxiety disorder and schizophrenia. Depression and Alzheimer's have preclinical data only.
Is CBD safe for neuropsychiatric conditions?
Clinical studies have consistently found CBD to be safe and well-tolerated. However, most trials have been short-term, and long-term safety data for neuropsychiatric use are limited.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02024APA
Elsaid, Sonja; Kloiber, Stefan; Le Foll, Bernard. (2019). Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.. Progress in molecular biology and translational science, 167, 25-75. https://doi.org/10.1016/bs.pmbts.2019.06.005
MLA
Elsaid, Sonja, et al. "Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.." Progress in molecular biology and translational science, 2019. https://doi.org/10.1016/bs.pmbts.2019.06.005
RethinkTHC
RethinkTHC Research Database. "Effects of cannabidiol (CBD) in neuropsychiatric disorders: ..." RTHC-02024. Retrieved from https://rethinkthc.com/research/elsaid-2019-effects-of-cannabidiol-cbd
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.